EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection

Josè Starvaggi, Santo Previti iD, Maria Zappalà iD, Roberta Ettari iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25084376 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Josè Starvaggi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 …. Hauptthemen laut MEDLINE: Antiviral Agents, Dengue, Protease Inhibitors, Zika Virus Infection. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: PRIN2022_PNRR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the global pandemic scenario, dengue and zika viruses (DENV and ZIKV, respectively), both mosquito-borne members of the flaviviridae family, represent a serious health problem, and considering the absence of specific antiviral drugs and available vaccines, there is a dire need to identify new targets to treat these types of viral infections. Within this drug discovery process, the protease NS2B/NS3 is considered the primary target for the development of novel anti-flavivirus drugs. The NS2B/NS3 is a serine protease that has a dual function both in the viral replication process and in the elusion of the innate immunity. To date, two main classes of NS2B/NS3 of DENV and ZIKV protease inhibitors have been discovered: those that bind to the orthosteric site and those that act at the allosteric site. Therefore, this perspective article aims to discuss the main features of the use of the most potent NS2B/NS3 inhibitors and their impact at the social level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsDengueProtease InhibitorsZika Virus InfectionAnimalsHumansDEAD-box RNA HelicasesDengue VirusNucleoside-TriphosphataseSerine EndopeptidasesViral Nonstructural ProteinsViral ProteasesZika Virus

Stichwörter der Autor:innen

NS2B/NS3 serine proteaseantiviral agentsdengue virusorthosteric and allosteric inhibitorszika virus

Substanzen

Antiviral AgentsDEAD-box RNA HelicasesNS2B protein, flavivirusNS3 protein, Zika virusNucleoside-TriphosphataseProtease InhibitorsSerine EndopeptidasesViral Nonstructural ProteinsViral Proteases

Autor:innen und Institutionen

  • Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Viale Ferdinando Stagno d'Alcontres 31, 98166 Messina, Italy.

ORCID-Profile: Santo Previti, Maria Zappalà, Roberta Ettari

Förderung

  • PRIN2022_PNRR

Zitieren

APA

Starvaggi, J., Previti, S., Zappalà, M., & Ettari, R. (2024). The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25084376

Vancouver

Starvaggi J, Previti S, Zappalà M, Ettari R. The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25084376

BibTeX
@article{Starvaggi2024,
  author = {Starvaggi, Josè and Previti, Santo and Zappalà, Maria and Ettari, Roberta},
  title = {The Inhibition of NS2B/NS3 Protease: A New Therapeutic Opportunity to Treat Dengue and Zika Virus Infection},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25084376}
}
Kostenlos starten →